NuvaRing 120+15 mikg/24 timer vaginalindlæg Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

nuvaring 120+15 mikg/24 timer vaginalindlæg

paranova danmark a/s - ethinylestradiol, etonogestrel - vaginalindlæg - 120+15 mikg/24 timer

Yasminelle 3,0 mg+0,020 mg filmovertrukne tabletter Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

yasminelle 3,0 mg+0,020 mg filmovertrukne tabletter

bayer ab - drospirenon, ethinylestradiol - filmovertrukne tabletter - 3,0 mg+0,020 mg

Yaz 3 mg+0,02 mg filmovertrukne tabletter Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

yaz 3 mg+0,02 mg filmovertrukne tabletter

bayer ab - drospirenon, ethinylestradiol - filmovertrukne tabletter - 3 mg+0,02 mg

VeraSeal Den Europæiske Union - dansk - EMA (European Medicines Agency)

veraseal

instituto grifols, s.a. - humant fibrinogen, human thrombin - hemostase, kirurgisk - antihemorrhagics - understøttende behandling hos voksne, hvor standard kirurgiske teknikker er utilstrækkelige:for forbedring af haemostasisas sutur støtte i karkirurgi.

Plerixafor Accord Den Europæiske Union - dansk - EMA (European Medicines Agency)

plerixafor accord

accord healthcare s.l.u. - plerixafor - multiple myeloma; hematopoietic stem cell transplantation - immunostimulants, - adult patientsplerixafor accord is indicated in combination with granulocyte-colony stimulating factor (g-csf) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma or multiple myeloma whose cells mobilise poorly (see section 4. paediatric patients (1 to less than 18 years)plerixafor accord is indicated in combination with g-csf to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children with lymphoma or solid malignant tumours, either:- pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilization with g-csf (with or without chemotherapy) is expected to be insufficient with regards to desired hematopoietic stem cells yield, or- who previously failed to collect sufficient haematopoietic stem cells (see section 4.